Company intelligence / Profile preview

Shiji Kangtai

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~1902
Development stage: Other

Overview

The company is a leading Chinese developer, manufacturer, and marketer of human vaccines; 11 vaccines have been approved for market launch or emergency use, including pioneering hepatitis B and pneumococcal conjugate vaccines. Some international approvals exist for COVID-19 vaccines.

Therapeutic areas: Infectious Diseases
Modalities: Live attenuated viral vaccineInactivated viral vaccineRecombinant protein vaccineBacterial polysaccharide vaccineBacterial polysaccharide conjugate vaccineCombination vaccineViral vector vaccinemRNA-based drugs
Industry: Pharma

Partnerships

Phil. Pharmawealth (Philippines distributor, COVID-19 vaccine)International business development in over 20 countries

Beyond the preview

Go deeper on Shiji Kangtai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shiji Kangtai.

Explore the full profile